US 11,850,270 B2
Probiotics and methods of use
Martha Rodgers Carlin, Lonetree, CO (US); Steven Karim Kazemi, Denver, CO (US); Naseer Sangwan, Chicago, IL (US); and Raul De Jesus Cano, San Luis Obispo, CA (US)
Assigned to The Biocollective, LLC, Denver, CO (US)
Appl. No. 16/770,064
Filed by The Biocollective, LLC, Denver, CO (US)
PCT Filed Dec. 4, 2018, PCT No. PCT/US2018/063784
§ 371(c)(1), (2) Date Jun. 4, 2020,
PCT Pub. No. WO2019/113023, PCT Pub. Date Jun. 13, 2019.
Claims priority of provisional application 62/594,201, filed on Dec. 4, 2017.
Prior Publication US 2021/0315948 A1, Oct. 14, 2021
Int. Cl. A61K 35/747 (2015.01); A61K 31/7004 (2006.01)
CPC A61K 35/747 (2013.01) [A61K 31/7004 (2013.01)] 19 Claims
 
1. A probiotic formulation comprising a mixture of viable microorganisms of the species Pediococcus acidilactici, Leuconostoc mesenteroides, and Lactobacillus reuteri, and a formulary ingredient selected from a binder, a diluent and an excipient, wherein the probiotic formulation increases the abundance of microbial gastrointestinal genes associated with mannitol production in a subject upon administration of the formulation to the subject.